221 related articles for article (PubMed ID: 33856059)
1. USP7 limits CDK1 activity throughout the cell cycle.
Galarreta A; Valledor P; Ubieto-Capella P; Lafarga V; Zarzuela E; Muñoz J; Malumbres M; Lecona E; Fernandez-Capetillo O
EMBO J; 2021 Jun; 40(11):e99692. PubMed ID: 33856059
[TBL] [Abstract][Full Text] [Related]
2. Restraining CDK1-cyclin B activation: PP2A on the cUSP(7).
Chow-Castro M; Dixon SD; Saldivar JC
EMBO J; 2021 Jun; 40(11):e108486. PubMed ID: 33969907
[TBL] [Abstract][Full Text] [Related]
3. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
[TBL] [Abstract][Full Text] [Related]
4. USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
[TBL] [Abstract][Full Text] [Related]
5. Targeting ubiquitin specific protease 7 in cancer: A deubiquitinase with great prospects.
Yeasmin Khusbu F; Chen FZ; Chen HC
Cell Biochem Funct; 2018 Jul; 36(5):244-254. PubMed ID: 29781103
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Li P; Liu HM
Eur J Med Chem; 2020 Apr; 191():112107. PubMed ID: 32092586
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A regulated by USP7 is polyubiquitinated and polyneddylated.
Do HA; Baek KH
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35593311
[TBL] [Abstract][Full Text] [Related]
8. USP7: Target Validation and Drug Discovery for Cancer Therapy.
Zhou J; Wang J; Chen C; Yuan H; Wen X; Sun H
Med Chem; 2018; 14(1):3-18. PubMed ID: 29065837
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
Li P; Liu Y; Yang H; Liu HM
Eur J Med Chem; 2021 Apr; 216():113291. PubMed ID: 33684824
[TBL] [Abstract][Full Text] [Related]
10. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
11. USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms.
Pozhidaeva A; Valles G; Wang F; Wu J; Sterner DE; Nguyen P; Weinstock J; Kumar KGS; Kanyo J; Wright D; Bezsonova I
Cell Chem Biol; 2017 Dec; 24(12):1501-1512.e5. PubMed ID: 29056420
[TBL] [Abstract][Full Text] [Related]
12. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
13. The deubiquitinase USP7 uses a distinct ubiquitin-like domain to deubiquitinate NF-ĸB subunits.
Mitxitorena I; Somma D; Mitchell JP; Lepistö M; Tyrchan C; Smith EL; Kiely PA; Walden H; Keeshan K; Carmody RJ
J Biol Chem; 2020 Aug; 295(33):11754-11763. PubMed ID: 32587091
[TBL] [Abstract][Full Text] [Related]
14. PP2A inhibitors arrest G2/M transition through JNK/Sp1- dependent down-regulation of CDK1 and autophagy-dependent up-regulation of p21.
Gong FR; Wu MY; Shen M; Zhi Q; Xu ZK; Wang R; Wang WJ; Zong Y; Li ZL; Wu Y; Zhou BP; Chen K; Tao M; Li W
Oncotarget; 2015 Jul; 6(21):18469-83. PubMed ID: 26053095
[TBL] [Abstract][Full Text] [Related]
15. The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy.
Nininahazwe L; Liu B; He C; Zhang H; Chen ZS
Drug Discov Today; 2021 Feb; 26(2):490-502. PubMed ID: 33157193
[TBL] [Abstract][Full Text] [Related]
16. USP7 is a SUMO deubiquitinase essential for DNA replication.
Lecona E; Rodriguez-Acebes S; Specks J; Lopez-Contreras AJ; Ruppen I; Murga M; Muñoz J; Mendez J; Fernandez-Capetillo O
Nat Struct Mol Biol; 2016 Apr; 23(4):270-7. PubMed ID: 26950370
[TBL] [Abstract][Full Text] [Related]
17. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
18. A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present).
Li P; Liu Y; Liu HM
Expert Opin Ther Pat; 2022 Jul; 32(7):753-767. PubMed ID: 35343357
[TBL] [Abstract][Full Text] [Related]
19. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability.
Ma H; Chen H; Guo X; Wang Z; Sowa ME; Zheng L; Hu S; Zeng P; Guo R; Diao J; Lan F; Harper JW; Shi YG; Xu Y; Shi Y
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):4828-33. PubMed ID: 22411829
[TBL] [Abstract][Full Text] [Related]
20. N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies.
Li M; Liu S; Chen H; Zhou X; Zhou J; Zhou S; Yuan H; Xu QL; Liu J; Cheng K; Sun H; Wang Y; Chen C; Wen X
Eur J Med Chem; 2020 Aug; 199():112279. PubMed ID: 32497973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
